Bevacizumab
Modify Date: 2024-01-02 11:13:03
Bevacizumab structure
|
Common Name | Bevacizumab | ||
|---|---|---|---|---|
| CAS Number | 216974-75-3 | Molecular Weight | 396.150 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H18ILiN2O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BevacizumabBevacizumab, as a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used for the research of cancer[1][2]. |
| Name | Lithium 4-{[2-(diethylamino)ethyl]carbamoyl}-2-iodobenzoate |
|---|---|
| Synonym | More Synonyms |
| Description | Bevacizumab, as a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used for the research of cancer[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Bevacizumab-loaded hydrogel results in significant tumor reduction. Bevacizumab is taken up by other organs, including the heart, lung, and spleen. Bevacizumab accumulates higher within tumors via Bevacizumab-loaded hydrogel administration from 14 days onward as compared to the solution formulation. Bevacizumab (I.v.) solution, a typical drug clearance profile is observed where the antibody is cleared from the circulatory system with a half-life of ~4~5 days. The Bevacizumab-loaded hydrogel and the weekly administration of Bevacizumab solution inhibits tumor growth/metastasis in the peritoneal cavity, while one-time i.v. injection of Bevacizumab solution does not provide any therapeutic effect, leading to extensive tumor metastasis[2]. |
| References |
| Molecular Formula | C14H18ILiN2O3 |
|---|---|
| Molecular Weight | 396.150 |
| Exact Mass | 396.052216 |
| Lithium 4-{[2-(diethylamino)ethyl]carbamoyl}-2-iodobenzoate |
| Benzoic acid, 4-[[[2-(diethylamino)ethyl]amino]carbonyl]-2-iodo-, lithium salt (1:1) |